Back to search

National and Kapodistrian University of Athens

Development and evaluation of a new Psysiologically Based Biopharmaceutics Modeling ( PBBM) approach for predicting oral drug product performance using the Open Systems Pharmacology Suite

Abstract

dc:description

Background and aimsThe oral route is preferred for drug administration due to high patient compliance, this comes withchallenges, as absorption from the gastrointestinal (GI) tract is a complex process. This is especially truefor poorly soluble Active Pharmaceutical Ingredients (APIs) and is associated with an increased risk of drugdevelopment failure. Animal studies are often used to mitigate this risk, but poor correlation with humanclinical data, along with ethical and economical concerns, drives the need for alternative in vitro and insilico approaches. Physiologically Based Biopharmaceutics Modeling (PBBM) offers such an alternative, integratingbiopharmaceutical parameters (e.g., solubility, dissolution) informed from in vitro experiments into Physiologically Based Pharmacokinetic (PBPK) models to predict clinical performance of the oral drugproduct. PBBM follows two main approaches: mechanistic and biomimetic. The mechanistic approach uses simpler dissolution experiments and enables extrapolation to untested clinical scenarios when all mechanisms are accounted for. The biomimetic approach employs more elaborate and biorelevant dissolution setups to closely mimic in vivo GI conditions, allowing predictions even with unknown mechanisms but limiting extrapolation to scenarios that have not been tested with these systems.The aim of this Thesis was to develop and evaluate a comprehensive, open-source PBBM workflow for predicting the performance of immediate-release drug products and enabling oral formulations after their administration in both fasted state and fed state conditions. The workflow integrates in vitro experimentation and in silico modeling tools to support mechanistic simulations of dissolution and absorption. In parallel, an approach for integrating data from the Biorelevant Gastrointestinal Transfer(BioGIT) system was developed to predict the clinical performance of enabling formulations, such as amorphous solid dispersions (ASDs) and salts. Methods and results To facilitate broader adoption of PBBM, a workflow was developed using free and open-source tools, including R and the Open Systems Pharmacology (OSP) suite. A new OSP solubility toolbox was developed in R-Shiny to characterize an APIs’ aqueous solubility-pH profile, affinity for surfactants (e.g., bile salts),and pH at the dissolving drug particle surface. Additionally, a new in silico dissolution module was developed in MoBi®, enabling the characterization of dissolution kinetics from in vitro experiments. This module accounts for medium properties (e.g., surfactant concentration, viscosity, pH) and hydrodynamic conditions (e.g., fluid volume, agitation rate). In vitro solubility and dissolution characteristics were seamlessly integrated into an updated PK-Sim® version, a whole-body PBPK modeling platform for predicting in vivo pharmacokinetics (PK). Updates included: implementation of the same MoBi® dissolution model, extended GI parameters (including population variability) and making these responsive to food and water intake based on a literature review. 7 Validation and case studies demonstrated the predictive capability of the workflow. The bile saltmicellization tool accurately described solubility behavior for 21 diverse APIs. The MoBi® dissolution module successfully reproduced in vitro dissolution profiles of glibenclamide, acalabrutinib, and vericiguatunder variable experimental conditions. For the poorly soluble basic vericiguat (Verquvo®), the integrated PBBM captured in vivo PK in fasted state and fed state, as well as following proton pump inhibitor (PPI) treatment which increases gastric pH. The fasted state PK were well predicted across the 1.25–15 mg doserange, and the impact of PPIs on maximum plasma concentration (C max ) and area under the plasma concentration-time curve (AUC) was captured, although time of C max (t max ) was underpredicted. The modelalso accurately reflected the increase in AUC following a high-fat, high-calorie meal. However, the observed increase in C max under fed conditions was not fully reproduced by the PBBM.The PBBM workflow was further extended to support the biomimetic approach by integrating data from the BioGIT system. In this approach, in vitro measured luminal concentrations were translated into administration protocols that delivered dissolved and solid API directly to GI segments (stomach, duodenum, upper jejunum). This method was explored using suspensions of posaconazole (Noxafil®) anditraconazole (Sporanox®) in the fasted state, and the itraconazole amorphous solid dispersion (ASD) inboth fasted state and fed state. The resulting PBBMs for posaconazole and itraconazole enabling formulations closely matched the clinically observed average profiles, for itraconazole, this included bothfasted state and fed state. Concluding remarksThis thesis developed and validated a free, open-source PBBM workflow within the OSP Suite, aimed atimproving oral absorption predictions while reducing reliance on animal studies and maintaining patientsafety. Key advances include:1. An OSP Solubility Toolbox and mechanistic dissolution module for bottom-up bioequivalence and dose predictions.2. Updates to the PK-Sim® gastrointestinal physiology and dissolution models, improving accuracy infasted, fed, and PPI-treated state predictions.3. A novel method integrating BioGIT experimental data into PBBM for posaconazole anditraconazole, accurately capturing formulation- and prandial-state differences.The modular design allows future expansion to complex formulations and diverse APIs through broader collaboration. By combining in vitro mechanistic insights with in silico modeling, this workflow provides arobust blueprint for biopharmaceutical risk assessment, formulation ranking, and regulatory adoption,supporting safer, more efficient oral drug product development.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2025

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Vrenken, Paul
  • Βρένκεν, Πόλ

Subjects

dc:subject × 11

Rights

Language dc:language
eng

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/61722

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Vrenken, Paul; Βρένκεν, Πόλ. Development and evaluation of a new Psysiologically Based Biopharmaceutics Modeling ( PBBM) approach for predicting oral drug product performance using the Open Systems Pharmacology Suite. National and Kapodistrian University of Athens, 2025. http://hdl.handle.net/10442/hedi/61722